title: A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
abstract: OBJECTIVE
  Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.
  
  
  METHODS
  Using a Markov state transition model, patient characteristics and survival data from the recent clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and intervention (assay consistent, hypothetical) cohorts were evaluated.
  
  
  RESULTS
  The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year saved (LYS), as compared to the baseline cohort. Cost-effectiveness was further demonstrated in platinum-sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per LYS and $2736 per LYS, respectively.
  
  
  CONCLUSIONS
  The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
authors.affiliation: Helomics™ Corporation, Pittsburgh, PA, United States.
authors.forename: Victoria
authors.initials: V
authors.lastname: Plamadeala
authors.affiliation: Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Kelley
authors.affiliation: Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.
authors.forename: John K
authors.initials: JK
authors.lastname: Chan
authors.affiliation: The Western Pennsylvania Hospital, Pittsburgh, PA, United States.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Krivak
authors.affiliation: Helomics™ Corporation, Pittsburgh, PA, United States.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Gabrin
authors.affiliation: Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Brower
authors.affiliation: Washington University School of Medicine, St. Louis, MO, United States.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Powell
authors.affiliation: Yale University School of Medicine, New Haven, CT, United States.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Rutherford
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, TX, United States.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
mesh_terms: D000077216:Carcinoma, Ovarian Epithelial; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D019008:Drug Resistance, Neoplasm; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000191:economics; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D016016:Proportional Hazards Models; D015996:Survival Rate; D014481:United States
chemical_list: D009944:Organoplatinum Compounds
keywords: Chemoresponse assay; Chemotherapy sensitivity and resistance assay (CSRA); Cost-effectiveness; Markov transition model; Ovarian cancer